Teragen Etex Signs Industry-Academic Agreement with Dongguk University for New Drug Development

Promotion of joint research and clinical trials for new drug candidates, and training of specialized talent in pharmaceutical bio fields

[Asia Economy Reporter Hyungsoo Park] Theragen Etex announced on the 21st that it has signed an industry-academic cooperation agreement (MOU) with Dongguk University College of Pharmacy for joint research and fostering talent in the pharmaceutical bio sector.

Ryu Byunghwan, CEO of Theragen Etex, and Kim Sanggeon, Dean of Dongguk University College of Pharmacy, held the signing ceremony at Dongguk University on the 16th. The two institutions will collaborate on ▲ joint research and clinical trials for new drug development ▲ training of pharmaceutical bio professionals ▲ joint use of research facilities and exchange of personnel and information. Through industry-academic joint research, they will also engage in activities for the commercialization of related technologies such as discovering new drug candidates and licensing out.

Ryu Byunghwan, CEO of Theragen Etex, stated, "We will enhance new drug development and pharmaceutical production capabilities by integrating the expertise of both institutions," adding, "Ultimately, through mutual competitiveness enhancement, we will achieve the fruits of global new drug development."

Kim Sanggeon, Dean of Dongguk University College of Pharmacy, introduced, "We will do our best to achieve practical results such as new drug development by combining academic fields pursued by the university, including data science, biostatistics in medicine, and medicinal chemistry, as well as translational medicine at Dongguk University Biomedicine Campus, with corporate capabilities."